Joann Hsu

2.0k total citations
78 papers, 961 citations indexed

About

Joann Hsu is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Joann Hsu has authored 78 papers receiving a total of 961 indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Pulmonary and Respiratory Medicine, 42 papers in Oncology and 24 papers in Molecular Biology. Recurrent topics in Joann Hsu's work include Renal cell carcinoma treatment (38 papers), Cancer Genomics and Diagnostics (20 papers) and Cancer Immunotherapy and Biomarkers (17 papers). Joann Hsu is often cited by papers focused on Renal cell carcinoma treatment (38 papers), Cancer Genomics and Diagnostics (20 papers) and Cancer Immunotherapy and Biomarkers (17 papers). Joann Hsu collaborates with scholars based in United States, Brazil and Canada. Joann Hsu's co-authors include Sumanta K. Pal, Nazlı Dizman, Paulo Gustavo Bergerot, Jeffrey M. Trent, Nicholas Salgia, Sarah K. Highlander, Manuel Caitano Maia, John D. Gillece, Megan Folkerts and Lauren Reining and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Joann Hsu

69 papers receiving 953 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joann Hsu United States	16	430	428	368	193	144	78	961
Hye Sung Won South Korea	22	376 0.9×	519 1.2×	289 0.8×	284 1.5×	227 1.6×	88	1.3k
M. Henar Alonso United States	19	179 0.4×	361 0.8×	220 0.6×	149 0.8×	397 2.8×	42	1.0k
Tian Tian China	19	229 0.5×	279 0.7×	242 0.7×	97 0.5×	86 0.6×	70	892
Shukui Wang China	21	579 1.3×	585 1.4×	212 0.6×	609 3.2×	183 1.3×	39	1.4k
Shiyu Xiao China	15	219 0.5×	192 0.4×	138 0.4×	112 0.6×	214 1.5×	33	846
Yoshihiro Hasui Japan	17	290 0.7×	199 0.5×	260 0.7×	237 1.2×	406 2.8×	32	1.0k
Naoe Goto Japan	22	199 0.5×	397 0.9×	190 0.5×	55 0.3×	203 1.4×	66	1.2k
Keisuke Kosumi Japan	24	434 1.0×	717 1.7×	468 1.3×	296 1.5×	707 4.9×	92	1.7k
Boram Han South Korea	17	241 0.6×	334 0.8×	342 0.9×	152 0.8×	160 1.1×	56	877
Ru Feng China	17	158 0.4×	319 0.7×	198 0.5×	88 0.5×	63 0.4×	93	998

Countries citing papers authored by Joann Hsu

Since Specialization

Citations

This map shows the geographic impact of Joann Hsu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joann Hsu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joann Hsu more than expected).

Fields of papers citing papers by Joann Hsu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joann Hsu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joann Hsu. The network helps show where Joann Hsu may publish in the future.

Co-authorship network of co-authors of Joann Hsu

This figure shows the co-authorship network connecting the top 25 collaborators of Joann Hsu. A scholar is included among the top collaborators of Joann Hsu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joann Hsu. Joann Hsu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ebrahimi, Hedyeh, Luís Meza, Nazlı Dizman, et al.. (2025). Cabozantinib (cabo) and nivolumab (nivo) with or without CBM588 in patients with metastatic renal cell carcinoma: Updated clinical outcomes of a phase I study.. Journal of Clinical Oncology. 43(5_suppl). 543–543. 1 indexed citations

Battle, Dena, Nicholas Salgia, Zeynep Büşra Zengin, et al.. (2024). Prevalence of Dietary Modification and Supplement Use in Patients with Metastatic Renal Cell Carcinoma Receiving Systemic Therapy. Nutrients. 16(11). 1630–1630. 1 indexed citations

Bergerot, Cristiane Decat, Errol J. Philip, Ameish Govindarajan, et al.. (2023). Changes in Perception of Cure Among Patients With Genitourinary Cancers Initiating Immune Checkpoint Inhibitors: A Longitudinal Study. Clinical Genitourinary Cancer. 21(6). 626–630.e3. 1 indexed citations

Chehrazi‐Raffle, Alex, Ramya Muddasani, Nazlı Dizman, et al.. (2023). Ultrasensitive Circulating Tumor DNA Pilot Study Distinguishes Complete Response and Partial Response With Immunotherapy in Patients With Metastatic Renal Cell Carcinoma. JCO Precision Oncology. 7(7). e2200543–e2200543. 10 indexed citations

Lu, Kun‐Han, Nazlı Dizman, Regina Barragán-Carrillo, et al.. (2023). CT-based radiomics model for the prediction of genomic alterations in renal cell carcinoma (RCC). The Oncologist. 28(Supplement_1). S15–S15.

Chawla, Neal Shiv, Nicolas Sayegh, Nishita Tripathi, et al.. (2022). Genomic and Clinical Prognostic Factors in Patients With Advanced Urothelial Carcinoma Receiving Immune Checkpoint Inhibitors. Clinical Genitourinary Cancer. 21(1). 69–75. 7 indexed citations

Zengin, Zeynep Büşra, Caroline Weipert, Nicholas Salgia, et al.. (2021). Complementary Role of Circulating Tumor DNA Assessment and Tissue Genomic Profiling in Metastatic Renal Cell Carcinoma. Clinical Cancer Research. 27(17). 4807–4813. 18 indexed citations

Bergerot, Cristiane Decat, Errol J. Philip, Paulo Gustavo Bergerot, et al.. (2020). Discrepancies between genitourinary cancer patients' and clinicians' characterization of the Eastern Cooperative Oncology Group performance status. Cancer. 127(3). 354–358. 22 indexed citations

Zengin, Zeynep Büşra, Caroline Weipert, Joann Hsu, et al.. (2020). 701O Assessment of circulating cell-free tumor DNA (ctDNA) in 847 patients (pts) with metastatic renal cell carcinoma (mRCC) and concordance with tissue-based testing. Annals of Oncology. 31. S553–S554. 1 indexed citations

10.

Dizman, Nazlı, Nicholas Salgia, Paulo Gustavo Bergerot, et al.. (2020). Race/Ethnicity and Survival in Metastatic Renal Cell Carcinoma: Outcomes for Patients Receiving First Line Targeted Therapies. 4(3). 159–166. 1 indexed citations

11.

Salgia, Nicholas, Paulo Gustavo Bergerot, Manuel Caitano Maia, et al.. (2020). Stool Microbiome Profiling of Patients with Metastatic Renal Cell Carcinoma Receiving Anti–PD-1 Immune Checkpoint Inhibitors. European Urology. 78(4). 498–502. 148 indexed citations

12.

Dizman, Nazlı, Paulo Gustavo Bergerot, Cristiane Decat Bergerot, Joann Hsu, & Sumanta K. Pal. (2019). Targeted Therapies Following First-Line Immune Checkpoint Inhibitor Combination in Metastatic Renal Cell Carcinoma: A Single Center Experience. 3(3). 171–176. 2 indexed citations

13.

Bergerot, Paulo Gustavo, Cristiane Decat Bergerot, Errol J. Philip, et al.. (2019). Targeted Therapy and Immunotherapy: Effect of Body Mass Index on Clinical Outcomes in Patients Diagnosed with Metastatic Renal Cell Carcinoma. 3(1). 63–70. 15 indexed citations

14.

Hsu, Joann, John P. Donnelly, Justin X. Moore, et al.. (2018). National characteristics of Emergency Department visits by patients with cancer in the United States. The American Journal of Emergency Medicine. 36(11). 2038–2043. 57 indexed citations

15.

Maia, Manuel Caitano, Paulo Gustavo Bergerot, Nazlı Dizman, et al.. (2017). Association of Circulating Tumor DNA (ctDNA) Detection in Metastatic Renal Cell Carcinoma (mRCC) with Tumor Burden. PubMed. 1(1). 65–70. 37 indexed citations

16.

Dizman, Nazlı, Sumanta K. Pal, Rebecca A. Nelson, et al.. (2016). Impact of race on survival following radical cystectomy for muscle-invasive bladder cancer (MIBC): Analysis of the US National Cancer Database (NCDB). Annals of Oncology. 27. vi276–vi276. 1 indexed citations

17.

Tew, Ben Yi, Sumanta K. Pal, Miaoling He, et al.. (2016). Vitamin K epoxide reductase expression and prostate cancer risk. Urologic Oncology Seminars and Original Investigations. 35(3). 112.e13–112.e18. 6 indexed citations

18.

Pal, Sumanta K., Xiwei Wu, Hanjun Qin, et al.. (2015). Stool Bacteriomic Profiling in Patients with Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor–Tyrosine Kinase Inhibitors. Clinical Cancer Research. 21(23). 5286–5293. 60 indexed citations

19.

Oladipupo, Sunday S., Craig Smith, Andrea Santeford, et al.. (2014). Endothelial cell FGF signaling is required for injury response but not for vascular homeostasis. Proceedings of the National Academy of Sciences. 111(37). 13379–13384. 103 indexed citations

20.

Pal, Sumanta K., Jonathan Yamzon, Virginia Sun, et al.. (2012). Paclitaxel-Based High-Dose Chemotherapy with Autologous Stem Cell Rescue for Relapsed Germ Cell Tumor: Clinical Outcome and Quality of Life in Long-Term Survivors. Clinical Genitourinary Cancer. 11(2). 121–127. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact